 |
16 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Trial primary completion date: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma (clinicaltrials.gov) - May 12, 2014
P2b, N=365, Terminated, Sponsor: Cytos Biotechnology AG
Trial primary completion date: Apr 2014 --> May 2014
- | CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Trial termination: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma (clinicaltrials.gov) - May 12, 2014
P2b, N=365, Terminated, Sponsor: Cytos Biotechnology AG
Trial primary completion date: Apr 2014 --> May 2014 Active, not recruiting --> Terminated; primary endpoint missed
- CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Trial completion date: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma (clinicaltrials.gov) - May 12, 2014
P2b, N=365, Terminated, Sponsor: Cytos Biotechnology AG
Active, not recruiting --> Terminated; primary endpoint missed Trial completion date: Apr 2015 --> May 2014
- CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Trial primary completion date: CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids (clinicaltrials.gov) - May 12, 2014
P2b, N=0, Withdrawn, Sponsor: Cytos Biotechnology AG
Trial completion date: Apr 2015 --> May 2014 Trial primary completion date: Sep 2015 --> May 2014
- CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Trial withdrawal: CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids (clinicaltrials.gov) - May 12, 2014
P2b, N=0, Withdrawn, Sponsor: Cytos Biotechnology AG
Trial primary completion date: Sep 2015 --> May 2014 Not yet recruiting --> Withdrawn
- CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Trial completion date: CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids (clinicaltrials.gov) - May 12, 2014
P2b, N=0, Withdrawn, Sponsor: Cytos Biotechnology AG
- CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Enrollment change: CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids (clinicaltrials.gov) - May 12, 2014
P2b, N=0, Withdrawn, Sponsor: Cytos Biotechnology AG
Not yet recruiting --> Withdrawn N=170 --> 0
- |||||| CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
New P2b trial: CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids (clinicaltrials.gov) - Mar 12, 2014
P2b, N=170, Not yet recruiting, Sponsor: Cytos Biotechnology AG
- ||| CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
Enrollment closed: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma (clinicaltrials.gov) - Nov 19, 2013
P2b, N=360, Active, not recruiting, Sponsor: Cytos Biotechnology AG
N=170 --> 0 Recruiting --> Active, not recruiting
- |||||| CYT-005-AllQbG10 / Kuros, vidutolimod (CMP-001) / Regeneron
New P2b trial: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma (clinicaltrials.gov) - Aug 26, 2012
P2b, N=360, Active, not recruiting, Sponsor: Cytos Biotechnology AG